KOSDAQBiotech & Pharma394420

RecensMedical

₩4,065▲ 1.75%2026-11-18 close
Market Cap
₩44.7B
Turnover
₩200M
Volume
60K
Shares out.
11M
PER
—
PBR
—
EPS
—
Dividend Yield
0.00%

PER, EPS, PBR and BPS are calculated in-house from the last 4 quarters (2025Q1–2025Q4) · Dividend yield is based on ₩0 per share · Prices as of the 2026-11-18 close

01

Report overview

Revenue up two straight quarters, losses persist

RecensMedical's revenue has grown for two consecutive quarters since the 2026 first-quarter low, but it still runs operating losses and has not yet reached break-even.

  1. 1

    Revenue rose 41.0% to KRW 8.83 billion in 2025, and the operating loss narrowed from KRW 14.2 billion to KRW 10.6 billion.

  2. 2

    By contrast, the net loss attributable to controlling shareholders widened from KRW 7.84 billion to KRW 19.1 billion, and press reports tied the increase mainly to higher financial costs.

  3. 3

    Quarterly revenue reached KRW 1.69 billion in the second quarter of 2026, up 65.3% from the prior quarter, and KRW 1.79 billion in the third quarter, up 6.0%.

  4. 4

    The first-half 2026 operating loss was KRW 5.2 billion, wider than KRW 4.1 billion a year earlier (preliminary, Sangsangin Securities analysis reported on October 19, 2026). A company official said 2026 revenue would fall short of the level presented at listing.

  5. 5

    The company keeps its target of reaching break-even in 2027, but has not yet presented specific order volumes or earnings guidance to support it.

02

Business structure

RecensMedical, founded in 2016, builds medical devices on a proprietary precision cooling platform that controls cryogenic refrigerant temperature within seconds. The company uses a modular structure in which products share one core technology and add functions depending on the intended use.

Its main products are the TargetCool skin precision cooling device, the OcuCool ophthalmic cooling anesthesia device, the TargetCool+ spray syringe and the VetEase veterinary cooling device.

Revenue recurs mainly through disposable parts such as cartridges and containers that are used with each procedure after the equipment is installed. According to a press report based on first-quarter 2026 data, TargetCool accounted for 69.38% of sales, VetEase for 6.47%, and other products combined for 13.82%.

Most sales pass through distributors rather than firm order backlogs, so the timing and size of individual distributor orders move quarterly results sharply.

On the customer side, C-customer sales, which had exceeded 10% of revenue, fell from KRW 1.4 billion in the first half of 2025 to KRW 400 million in the first half of 2026, showing the volatility of concentrated accounts.

Overseas, TargetCool has traded with 44 countries as of January 2026, and VetEase has a distributor network in eight countries. The company plans to bring OcuCool, which holds FDA De Novo authorization, into the US intravitreal injection market from 2027.

The company points to more than 150 domestic and international patents and certifications as its competitive edge.

03

Earnings trend

Quarterly revenue · Operating profit
RevenueOperating profit
Annual revenue · Operating profit
RevenueOperating profit
Quarterly results · Last 5 quarters
QuarterRevenueOperating profitOp. margin
2025Q3———
2025Q4———
2026Q1₩1B——
2026Q2₩1.7B——
2026Q3₩1.8B——
Annual results
YearRevenueOperating profitNet income (parent)Op. marginROEDebt-to-equity
2024₩6.3B-₩14.2B-₩7.8B−226.2%—−122.2%
2025₩8.8B-₩10.6B-₩19.1B−120.5%−274.0%72.1%

Consolidated basis (financial statements including subsidiaries) · Final figures from DART filings · Net income attributable to owners of the parent · Data as of 2026-11-14

04

Earnings analysis

On a disclosed basis, annual revenue rose 41.0% from KRW 6.26 billion in 2024 to KRW 8.83 billion in 2025. Over the same period the operating loss narrowed from KRW 14.2 billion to KRW 10.6 billion, and the operating margin improved from -226.2% to -120.5%.

The company has posted losses in two consecutive years, 2024 and 2025, and 2025 was the year in which the operating loss was smaller. The net loss attributable to controlling shareholders, however, widened from KRW 7.84 billion to KRW 19.1 billion, moving in the opposite direction to the operating loss.

The net loss including non-controlling interests was also disclosed as KRW 7.84 billion in 2024 and KRW 19.1 billion in 2025.

A September 2026 press report said that in the first half of 2025, derivative valuation losses on redeemable convertible preferred shares of KRW 4.5 billion and financial liability valuation losses of KRW 1.8 billion lifted financial costs to KRW 8.8 billion, and a business-report-based analysis showed full-year 2025 financial costs at the same KRW 8.8 billion.

Operating cash flow was -KRW 9.73 billion in 2024 and -KRW 8.59 billion in 2025, so the outflow narrowed but remains negative. Total equity at the end of 2025 was KRW 6.98 billion and total liabilities were KRW 5.03 billion, giving a debt ratio of 72.1%.

The 2024 debt ratio of -122.2% reflects a period when total equity was negative. Quarterly revenue went from KRW 1.02 billion in the first quarter of 2026 to KRW 1.69 billion in the second quarter, up 65.3% from the prior quarter, and KRW 1.79 billion in the third quarter, up 6.0%.

A wisereport summary put first-quarter 2026 revenue down 54.7% from a year earlier. First-half 2026 revenue was KRW 2.7 billion and the operating loss was KRW 5.2 billion, according to a Sangsangin Securities analysis (preliminary, reported October 19, 2026).

The same coverage noted that the first-half net loss of KRW 4.7 billion, down from KRW 12.7 billion a year earlier, reflected lower financial costs more than an improvement in the core business.

05

Industry analysis

The company operates in the cooling medical device market, where systems used in skin and eye procedures aim to reduce pain and shorten treatment time. According to the company, cooling devices can shorten procedures and ease pain, which is driving demand in clinical settings.

The company positions its products against heat-based devices, which it says require recovery time after treatment, and promotes a painless procedure. Companies such as NewIne and Microt are grouped with it as similar ophthalmic device makers on a company information site.

On the technology side, the FDA De Novo authorization for OcuCool, granted for a new type of device without an existing predicate, works as an entry barrier. Revenue recurs as consumables sell after equipment is installed, so consumable sales should grow as the installed base widens.

The installed base is still limited, and results depend heavily on distributor order timing. Press coverage notes that B2B adoption requires repeated rigorous validation periods, which limits the speed of market penetration.

The company therefore seeks to complement recurring revenue with B2C products such as a home beauty device. Its overseas distribution reaches 44 countries for TargetCool, and it has set a strategy of adding country-specific sales staff and expanding long-term exclusive supply contracts.

06

Outlook

At listing the company presented 2026 revenue of roughly KRW 18.9 billion to KRW 19.1 billion, although the figure varied across reports. After first-half 2026 revenue reached KRW 2.7 billion, a company official said 2026 revenue would come in below the level presented at listing.

Sangsangin Securities estimated 2026 full-year revenue at KRW 9.02 billion and an operating loss of KRW 8.77 billion (estimate reported October 19, 2026).

Reaching break-even in 2027 remains the company's stated target, while 2027 revenue estimates cited in the listing process differed by report, at KRW 29.7 billion with an operating profit of KRW 8.8 billion (January 2026 report) and KRW 29.1 billion with an operating profit of KRW 8.2 billion (September 2026 report).

Second-half strategies include new contracts, wider sales of a home beauty device and higher exports (September 2026 report). A home device launch was scheduled for the third quarter of 2026, and sales after launch can be checked in the 2026 business report.

Sangsangin Securities cited a TargetCool supply contract in China as an expected fourth-quarter 2026 development. Full-scale entry into the US intravitreal injection market is planned for 2027.

The KRW 15.4 billion raised in the IPO, including about KRW 4.8 billion for facilities to bring processes in-house, will be used in stages over three years for clinical and regulatory work and global marketing. The company also plans to internalize cartridge production to improve cost competitiveness and profitability.

07

Valuation

PER
—
PBR
—
ROE
-274.0%
EPS
—
BPS
—
Dividend per share
₩0

Because the net loss attributable to controlling shareholders totaled KRW 19.1 billion over the last four quarters, the price-to-earnings ratio cannot be calculated. The company has not returned cash to shareholders through dividends.

The valuation at listing was built on an assumption of a return to profit in 2027, so earnings-based multiples cannot be compared until profit appears. An IB Tomato report dated November 2026 said the share price was about half the IPO offer price.

The stock surged right after listing and then quickly gave back those gains. Total equity rose from the end of 2025 as IPO proceeds came in, and market capitalization still sits at a premium to net assets.

The key to reading valuation is whether the company returns to profit in 2027 and whether quarterly revenue keeps rising.

PER, EPS, PBR and BPS are all calculated in-house (the same method as Naver and Toss) · Dividend yield = cash dividend per share from DART filings (supplemented by KRX) ÷ current price · As of 2026-11-14

08

Bull factors

FDA De Novo authorized technology

The OcuCool ophthalmic cooling anesthesia device became the first Korean medical device company to win FDA De Novo authorization, a route for devices with no predicate technology. The company cites more than 150 domestic and international patents and certifications, plus key approvals in 24 countries.

Its modular structure, which shares one precision cooling platform, is presented as a consistent path for product expansion.

Revenue recovery in Q2 and Q3 2026

Revenue reached KRW 1.69 billion in the second quarter of 2026, up 65.3% from the prior quarter, and rose again to KRW 1.79 billion in the third quarter. Two consecutive quarterly gains after the first-quarter trough can be read as an early sign that orders are returning. Whether this becomes a trend will be clearer from full-year 2026 revenue in the business report.

Overseas distribution and cost-improvement plans

TargetCool has traded with 44 countries as of January 2026, and the company has set expanding long-term exclusive supply contracts as a strategy. It also plans to in-source carbon dioxide cartridge production to improve cost competitiveness and profitability.

09

Bear factors

Gap from earnings outlook presented at listing

In the listing process the company projected 2026 revenue of KRW 19.1 billion and an operating loss of KRW 400 million, but a press report said first-half 2026 revenue of KRW 2.7 billion reached only 14.2% of the full-year projection.

A company official also said revenue would come in below the level presented at listing. The first-half operating loss already exceeds the full-year estimate, making the target a test in the quarters ahead.

Order volatility and customer concentration

According to press coverage, revenue estimates based on minimum order quantities do not guarantee binding purchase orders. Most revenue flows through distributors, so the timing of each distributor's orders drives results.

C-customer sales fell from KRW 1.4 billion in the first half of 2025 to KRW 400 million in the first half of 2026.

Continued losses and cash outflow

Operating cash flow was -KRW 8.59 billion in 2025, and the net loss attributable to controlling shareholders widened to KRW 19.1 billion. The CEO has said selling and administrative expenses, largely for R&D, run at about KRW 10 billion a year. The KRW 15.4 billion raised in the IPO is planned for use in stages over three years.

10

Risk factors

Missed targets and delayed return to profit

Because the 2026 revenue and operating loss expectations presented at listing have already come down, the return-to-profit target for 2027 is itself open to test. The company maintains its 2027 break-even goal but has not provided specific order volumes or guidance. If revenue falls short, fixed costs such as R&D will keep pressure on earnings.

Shareholder structure and selling pressure

An IB Tomato report dated November 2026 said the maturity of the LB Technology Finance Fund No. 1 is approaching. The fund was reported to hold 650,000 shares as of the end of June 2026. Filings on large shareholding changes also record on-exchange sales in June 2026.

Legal dispute and product concentration

Money Today reported in January 2026 that a US counterparty arbitration ruling in July 2025 favored the company, but a retrial petition and appeal in a Texas court leave uncertainty. TargetCool also accounts for most revenue, so any problem with that single product would hit total sales directly.

11

What to watch next

  1. After November 2026

    The maturity of the LB Technology Finance Fund No. 1 and how its shares are handled. Whether maturing holdings reach the market is a variable directly tied to share supply and price action.

  2. Q4 2026

    Whether the TargetCool supply contract in China is signed. Sangsangin Securities cited it as an expected fourth-quarter factor in an October 2026 report.

  3. By end of March 2027

    Submission of the 2026 business report. It is the point to check how far full-year revenue sits from the listing-stage target and how the operating loss and financial costs changed.

  4. During 2027

    The planned US IVT market entry for OcuCool and the break-even target. The benchmark is whether quarterly revenue approaches the level needed for profit.

12

Overall view

RecensMedical grew revenue to KRW 8.83 billion in 2025, up 41.0%, but the operating loss of KRW 10.6 billion and the net loss attributable to controlling shareholders of KRW 19.1 billion show that losses persist.

Quarterly revenue rose in the second and third quarters of 2026, moving the trend toward recovery, yet first-half 2026 revenue of KRW 2.7 billion reached only 14.2% of the full-year projection given at listing.

A company official said 2026 revenue would come in below the level presented at listing, and Sangsangin Securities estimated the 2026 operating loss at KRW 8.77 billion.

Strengths include FDA De Novo authorized technology, distribution with 44 countries and recurring consumable revenue, while weaknesses include distributor order volatility, lower C-customer sales and a net loss improvement that rests on lower financial costs.

The 2027 break-even target remains the company's stated goal, but no specific order volumes or guidance have been provided to support it.

The next checkpoints are full-year revenue and operating margin in the 2026 business report, the handling of shares from the LB Technology Finance Fund No. 1 maturity, and whether the China supply contract is signed.

13

Sources

  1. Korea Exchange (KRX) — Prices · Market Cap · Volume
  2. FSS electronic disclosure system (DART) — Financial statements · Dividend filings
Show 18 more articles and sources
  1. innoforest.co.kr
  2. pharm.edaily.co.kr
  3. thevc.kr
  4. hitnews.co.kr
  5. lifescienceweek.com
  6. news.nate.com
  7. medicaltimes.com
  8. jumpit.saramin.co.kr
  9. sedaily.com
  10. m.news.nate.com
  11. comp.wisereport.co.kr
  12. medipana.com
  13. bizmetric.co.kr
  14. m.news.nate.com
  15. mt.co.kr
  16. ibtomato.com
  17. mt.co.kr
  18. seoulexchange.kr

Report written 2026-11-14 · Data as of 2026-11-13

This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.

Other reports in this industry

View industry analysis